Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 23074142)

1.

Pathway index models for construction of patient-specific risk profiles.

Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C.

Stat Med. 2013 Apr 30;32(9):1524-35. doi: 10.1002/sim.5641. Epub 2012 Oct 16.

2.

[Genomic basis for breast cancer: advances in personalized medicine].

Hidalgo-Miranda A, Jiménez-Sánchez G.

Salud Publica Mex. 2009;51 Suppl 2:s197-207. Review. Spanish.

3.

Ovarian cancer: markers of response.

Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ.

Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S21-9. doi: 10.1111/IGC.0b013e3181c2aeb5. Review.

PMID:
19955910
4.

"Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.

Glinsky GV.

J Clin Oncol. 2008 Jun 10;26(17):2846-53. doi: 10.1200/JCO.2008.17.0266. Review.

PMID:
18539963
5.

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.

Carr KM, Rosenblatt K, Petricoin EF, Liotta LA.

Hum Genomics. 2004 Jan;1(2):134-40. Review.

6.

Genomic prediction in animals and plants: simulation of data, validation, reporting, and benchmarking.

Daetwyler HD, Calus MP, Pong-Wong R, de Los Campos G, Hickey JM.

Genetics. 2013 Feb;193(2):347-65. doi: 10.1534/genetics.112.147983. Epub 2012 Dec 5. Review.

7.

Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.

Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M.

Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R153-7. Epub 2003 Aug 19. Review.

8.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
9.

Genomic signatures associated with the development, progression, and outcome of prostate cancer.

Mendiratta P, Febbo PG.

Mol Diagn Ther. 2007;11(6):345-54. Review.

PMID:
18078352
10.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

11.

Genomic analysis of epithelial ovarian cancer.

Farley J, Ozbun LL, Birrer MJ.

Cell Res. 2008 May;18(5):538-48. doi: 10.1038/cr.2008.52. Review.

12.

Genomic and personalized medicine: foundations and applications.

Ginsburg GS, Willard HF.

Transl Res. 2009 Dec;154(6):277-87. doi: 10.1016/j.trsl.2009.09.005. Epub 2009 Oct 1. Review.

PMID:
19931193
13.

The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.

Khalil I, Brewer MA, Neyarapally T, Runowicz CD.

Gynecol Oncol. 2010 Feb;116(2):282-5. doi: 10.1016/j.ygyno.2009.10.085. Review.

PMID:
19931138
14.

Biomarker discovery in epithelial ovarian cancer by genomic approaches.

Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ.

Adv Cancer Res. 2007;96:1-22. Review.

PMID:
17161674
15.
16.

[From population genetics to population genomics of forest trees: integrated population genomics approach].

Krutovskiĭ KV.

Genetika. 2006 Oct;42(10):1304-18. Review. Russian.

PMID:
17152702
17.

Overview of personalized medicine in the disease genomic era.

Hong KW, Oh B.

BMB Rep. 2010 Oct;43(10):643-8. doi: 10.5483/BMBRep.2010.43.10.643. Review.

19.

Clinical utility of cancer family history collection in primary care.

Wilson B, Qureshi N, Little J, Santaguida P, Carroll J, Allanson J, Keshavarz H, Raina P.

Evid Rep Technol Assess (Full Rep). 2009 Apr;(179):1-94. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk